Market Surge and Regulatory Concerns on Bitcoin ETFs

Listen to this blog
Speed

Market Surge and Regulatory Concerns on Bitcoin ETFs

The Securities and Exchange Commission (SEC) released a false post claiming the approval of Bitcoin exchange-traded funds. The price of Bitcoin surged to $48,000 before SEC Chair Gary Gensler made it clear that the post was unauthorised, officially disavowing it. This post came on the eve of an expected decision by the SEC on the approval of Bitcoin ETFs, making the post appear to be real.

A SEC spokesperson stated that the SEC will take appropriate action and expressed concern about potential market manipulation in the cryptocurrency space.

The price of Bitcoin has since returned to $46,000. This fluctuation highlights the risks associated with misinformation in the cryptocurrency markets.

The crypto community is expecting a verified decision by the SEC today, as multiple funds are in the final stages of the approval process. The fate of Bitcoin ETFs remains uncertain. Do you think they will be approved, denied, or delayed again?

The above is for educational purposes only and does not constitute advice. You should always contact your advisor for a personal consultation.

*No liability can be accepted for any actions taken or refrained from being taken, as a result of reading the above.

More Articles

Global Bond Selloff: What Should You Be Doing & Norway’s Sovereign Wealth Fund Reduces US Government Bond Weighting

Right now, governments around the world are paying more to borrow money than at any point in decades. Also, Norway’s sovereign wealth fund, valued at over $2.3 trillion, is reducing the government subindex of its bond holdings.

AI Reaches Profitability & Gold is Still the Golden Ticket

Nvidia just smashed all expectations by posting over $96 billion in revenue in 90 days. Also, Gold is still on track for its biggest gain since 1999.

What The Markets Mean for Your Money & Healthcare Boom

Anthropic is preparing for its IPO listing. Elsewhere, pharmaceutical giant Moderna’s stock doubled this week after positive feedback on its melanoma cancer vaccine.

Ideas To Ignite Your Portfolio

Will 2025 be different than 2024?

7th

January

15:00 LONDON
16:00 BRUSSELS
19:00 DUBAI
23:00 HONG KONG